Australia: Infrastructure and Innovations for Clinical Trials

Sponsors seeking venues for pharmaceutical research and development would do well to consider Australia – offering a highly favorable, stable environment and experienced, capable local expertise. This article is the second in a three-part series: Here, we examine the landscape for clinical trials, including infrastructure, government funding support and incentives, patient centricity, patient recruitment, and the adoption of innovation.

Interested in more? Check out part 1 and part 3.


Open PDF

Return to Insights Center

Related Insights

Article

Australia: The Regulatory and Reimbursement Environment

Aug 28, 2023

Blog

Decentralized Trials: Considerations for Building a New Patient-Centric Model

May 13, 2021

Blog

Highlights from ISMPP Asia Pacific Meeting 2021

Sep 20, 2021

Report

New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023

Report

New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023

Video

Part 2: Risk-based Quality Management Video (RBQM) Series

Nov 11, 2021

Report

New Medicines, Novel Insights: Achieving patient-guided drug development

Oct 30, 2023

Blog

A patient-centric approach to managing clinical trial complexity

Jul 13, 2021

Video

The FDAs Race and Ethnic Diversity Plan Guidance: How prepared is your organization?

Feb 1, 2023

Article

Decentralized clinical trials - A more patient-centric approach

May 10, 2021

Blog

Including patients in DCT design

Sep 13, 2022

Blog

Adapting the validation process for PROs for rare diseases and other diseases with large unmet need and/or rapid progression

Apr 23, 2024